Châtillon, France, June 03, 2025




DBV Technologies announces the filing of an addendum to the 2024
Universal Registration Document

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT), a clinical-stage biopharmaceutical company (the “Company”), today
announced today the filing of an addendum to the 2024 Universal Registration
Document (the “Addendum”) with the French market authority, “Autorité des
Marchés Financiers” (“AMF”).

This Addendum provides an update to the Board of Directors' Corporate
Governance Report to account for the exceptional compensation granted to the
Chief Executive Officer by the Board of Directors during its meeting on April 30,
2025. The payment of this exceptional compensation remains subject to the
approval of the Annual Combined General Meeting to be held on June 11, 2025.

The URD and the addendum are available on the Company’s website at :
https://dbv-technologies.com and on the AMF website: https://amf-france.org/fr.
Printed copies of both documents are available, free of charge, at the Company’s
headquarters and registered office located at 107, avenue de la République, 92320
Châtillon, France.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV Technologies is currently focused on
investigating the use of its proprietary technology platform, Viaskin, to address food
allergies, which are caused by a hypersensitive immune reaction and characterized
by a range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including young children.
Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed
to introduce microgram amounts of a biologically active compound to the immune
system through intact skin. EPIT is a new class of non-invasive treatment that seeks
to modify an individual’s underlying allergy by re-educating the immune system to
become desensitized to allergen by leveraging the skin’s immune tolerizing
properties. DBV Technologies is committed to transforming the care of food allergic
people. The Company’s food allergy programs include ongoing clinical trials of
Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4
through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company’s ordinary shares are traded on segment B
of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT –
CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us
on X (formerly Twitter) and LinkedIn.


Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com